Activist investor Kevin Tang takes the CEO chair at Aurinia, replacing the entire C-suite

Kevin Tang does not do things halfway.

According to an 8-K filing on Monday, Tang — already chairman of the board at Aurinia Pharmaceuticals — has appointed himself chief executive officer, effective March 23. He simultaneously installed two longtime colleagues from Tang Capital Management, his life sciences investment firm, as COO and CFO. Four executives are out: CEO Peter Greenleaf, COO Matthew Donley, Chief Medical Officer Gregory Keenan, and CFO Joseph Miller all ceased serving as officers effective March 20, as first reported by Max Gelman at Endpoints News.

Greenleaf resigned from the board the following day and will stay on as a consultant for three months at $600 per hour to help with the transition.

This is not a subtle management refresh. It is one investor consolidating total operational control of a commercial-stage biotech company — the final move in a two-year campaign that passed through a shareholder revolt, a rogue FDA official, a defamation lawsuit, and a stock crash.

The two-year siege

The roots go back to mid-2024, when four Aurinia board directors — including Greenleaf — failed to win majority shareholder support at the annual meeting. Executive compensation also failed. The stock had fallen from roughly $35 to $8 under Greenleaf's tenure, and activist shareholders wanted blood.

By September 2024, a compromise emerged: the board shrank from nine to seven members, and Kevin Tang joined as chairman. Greenleaf survived — barely.

That survival was temporary. In April 2025, concerned shareholders announced their intention to withhold support for Greenleaf at the upcoming annual meeting and demanded his resignation. By July, Tang Capital had bought 1.2 million additional shares — an $11 million insider purchase that sent a clear signal about where this was heading.

The FDA official who tried to destroy the drug

Then the story took a turn nobody saw coming.

On September 29, 2025, George Tidmarsh — then head of the FDA's Center for Drug Evaluation and Research — posted on LinkedIn that LUPKYNIS, Aurinia's only marketed product, "has not been shown to provide a direct clinical benefit for patients." Aurinia's stock dropped 20 percent in a single session, wiping out roughly $350 million in market value.

The post was not a dispassionate regulatory assessment. According to court filings in the subsequent defamation lawsuit, Tidmarsh had a long personal history with Tang. The two had clashed at La Jolla Pharmaceutical, Odonate Therapeutics, and American Laboratories Holdings, with Tang involved in ousting Tidmarsh from leadership at all three companies. Tidmarsh had allegedly sent Tang threatening text messages — "The pain is not over," "I'm Not powerless," "more bad karma to come" — and the lawsuit alleged attempted bribery.

The LinkedIn post was deleted after internal FDA ethics concerns surfaced. On November 2, 2025, Tidmarsh resigned as CDER head after an HHS ethics investigation. The next day, Aurinia filed a defamation lawsuit against him in Maryland federal court.

An FDA regulator with a personal vendetta publicly declared your drug doesn't work, cratered your stock, got caught, and resigned. It would be rejected as a screenplay for being too on-the-nose.

Follow the money

Here is where it gets interesting from a shareholder perspective: Tang Capital continued buying through the chaos. A 13D/A filing disclosed that Tang Capital beneficially owned 9.2 percent of Aurinia's outstanding shares as of late February 2026, having spent approximately $26.3 million on open-market purchases since March 2025. On February 27, Tang bought another $7.2 million in stock at roughly $14 per share.

Three weeks later, he's CEO.

All of this was disclosed, and there is no suggestion of illegality. But the timeline tells its own story: the Tidmarsh-induced stock crash gave Tang an opportunity to accumulate shares at depressed prices, and the accumulation gave him the leverage to finish what the 2024 shareholder revolt started.

The drug is fine

To be clear about what Tang is inheriting: this is not a distressed asset.

LUPKYNIS (voclosporin), approved by the FDA in January 2021 as the first oral therapy for active lupus nephritis in adults, is growing. The company's full-year 2025 net product sales came in around $270 million, up roughly 25 percent year over year. Q3 2025 alone hit $70.6 million with $31.6 million in net income. The company has approximately $398 million in cash and has been buying back its own stock. Aurinia's 2026 guidance projects $305–315 million in LUPKYNIS sales.

This matters because Tang's usual playbook is different. Through Concentra Biosciences, a separate entity he controls, Tang has made a name buying distressed biotechs — companies with failed drugs or shrinking revenue — to shut them down and liquidate assets. STAT News has described Concentra's strategy as buying "zombie biotech companies." Seven buyout bids in the first half of 2025 alone.

Aurinia is the opposite of a zombie. It's profitable, growing, and sitting on nearly $400 million in cash. So the question becomes: is this the exception to the pattern, or a different version of the same play?

The new team

Tang brought his own people. Ryan Cole, 39, the new COO, has worked at Tang Capital since 2014 and previously held roles at Odonate Therapeutics. Michael Hearne, 63, the new CFO, has been CFO of Tang Capital since 2015 and previously held the same title at La Jolla Pharmaceutical and Odonate. Both will receive $300,000 base salaries with 50 percent target bonuses and options on 150,000 shares.

Tang himself has elected to take no salary, bonus, or equity awards.

The board also created a new Lead Independent Director role and appointed Craig Johnson, an existing independent member, to fill it — a governance fig leaf for a company where the chairman, CEO, and two top executives all report to the same person.

What to watch

The tell will be the pipeline. Aurinia has been developing aritinercept, a next-generation autoimmune therapy, with clinical studies initiated and an additional trial planned for Q2 2026. If Tang invests in expanding that program, it signals he's building. If he deprioritizes it and runs the company lean on LUPKYNIS cash flows alone, the endgame is almost certainly a sale.

Tang's career arc is consistent: take a concentrated position, take governance control, optimize for an exit. Ardea went to AstraZeneca. La Jolla went to Innoviva. He's now running a profitable lupus drug company with no salary, his own team in every chair, and $400 million in the bank.

For anyone in the autoimmune space watching this, the most interesting question isn't whether Tang can run a biotech. It's who he's running it for.